Orphazyme's Arimoclomol Disappoints For Muscle-Wasting Disorder

Pivotal Trial Failure For ‘Pipeline-In-A-Product’

 
• By Kevin Grogan
  
mermaid
Denmark's Orphazyme reflects on disappointing data • Source: Shutterstock

More from Rare Diseases

More from Scrip